Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.

OBJECTIVE To estimate the cost-effectiveness of periodic screening for mild thyroid failure by measurement of serum thyroid stimulating hormone (TSH) concentration. DESIGN Cost-utility analysis using a state-transition computer decision model that accounted for case finding, medical consequences of mild thyroid failure, and costs of care during 40 years of simulated follow-up. SETTING Periodic health examinations in offices of primary care physicians. PATIENTS Hypothetical cohorts of women and men screened every 5 years during the recommended periodic examination, beginning at age 35 years. INTERVENTIONS Adding the serum TSH assay to total serum cholesterol screening was compared to cholesterol screening alone. MAIN OUTCOME MEASURES Discounted quality-adjusted life years (QALYs) and direct medical costs from a societal perspective. RESULTS The cost-effectiveness of screening 35-year-old patients with a serum TSH assay every 5 years was $9223 per QALY for women and $22595 per QALY for men. The cost-effectiveness became more favorable when age at first screening was increased for both sexes and was always more favorable for women than men. Reduced progression to overt hypothyroidism and relief of symptoms increased QALYs, but did not substantially reduce direct medical costs. Finding hypercholesterolemia induced by mild thyroid failure reduced direct medical costs, but did not substantially increase QALYs. The cost of a TSH assay and the importance to patients of symptoms associated with thyroid failure were the most influential factors in sensitivity analyses. CONCLUSIONS The cost-effectiveness of screening for mild thyroid failure compares favorably with other generally accepted preventive medical practices. Physicians should consider measuring serum TSH concentration in patients aged 35 years and older undergoing routine periodic health examinations. The cost-effectiveness of screening is most favorable in elderly women.

[1]  K. A. Cullen,et al.  Hospital costs of revascularization procedures for femoropopliteal arterial disease. , 1994, Journal of vascular surgery.

[2]  B. Littenberg,et al.  Screening for hypertension. , 1970, Lancet.

[3]  W. Wiersinga,et al.  Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. , 1995, Archives of internal medicine.

[4]  J. French,et al.  The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham Survey , 1995, Clinical endocrinology.

[5]  H. D. de Koning,et al.  Breast cancer screening and cost‐effectiveness; Policy alternatives, quality of life considerations and the possible impact of uncertain factors , 1991, International journal of cancer.

[6]  W. Patsch,et al.  Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. , 1990, Archives of internal medicine.

[7]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  R. Riemersma,et al.  END‐ORGAN RESPONSES TO THYROXINE THERAPY IN SUBCLINICAL HYPOTHYROIDISM , 1985, Clinical endocrinology.

[9]  M. Carroll,et al.  Serum lipids of adults 20-74 years: United States, 1976-80. , 1993, Vital and health statistics. Series 11, Data from the National Health Survey.

[10]  A. Mushlin,et al.  Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians. Part 1. , 1996, Annals of internal medicine.

[11]  L Goldman,et al.  Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  David Haber,et al.  Guide to clinical preventive services: a challenge to physician resourcefulness , 1993 .

[13]  H. Arntz,et al.  Subclinical hypothyroidism and hyperlipoproteinaemia: indiscriminate L-thyroxine treatment not justified. , 1993, Acta endocrinologica.

[14]  J. Franklyn,et al.  Thyroxine replacement therapy and circulating lipid concentrations , 1993, Clinical endocrinology.

[15]  H. Yoshimura,et al.  Disturbed lipid metabolism in patients with subclinical hypothyroidism: effect of L-thyroxine therapy. , 1994, Internal medicine.

[16]  D. Cooper,et al.  L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. , 1984, Annals of internal medicine.

[17]  G. Oster,et al.  Cost‐effectiveness of Ticlopidine in Preventing Stroke in High‐risk Patients , 1994, Stroke.

[18]  J. French,et al.  Natural history of autoimmune thyroiditis. , 1981, British medical journal.

[19]  J. Dolovich,et al.  The need for extended treatment of anaphylaxis. , 1980, Canadian Medical Association journal.

[20]  D. Rodbard,et al.  Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. , 1981, The Journal of clinical endocrinology and metabolism.

[21]  G. Guyatt,et al.  Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. , 1991, The American journal of cardiology.

[22]  J. Franklyn,et al.  Prevalence and follow‐up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom , 1991, Clinical endocrinology.

[23]  M. Helfand,et al.  Screening for thyroid disease. , 1990, Annals of internal medicine.

[24]  L. Schneiderman,et al.  The "abnormal" screening serum thyroxine (T4): analysis of physician response, outcome, cost and health effectiveness. , 1981, Journal of chronic diseases.

[25]  D. Zauli,et al.  Thyroid failure in the elderly. , 1988, JAMA.

[26]  D. Appleton,et al.  THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY , 1977, Clinical endocrinology.

[27]  J. Goodwin,et al.  Thyroid failure in the elderly. Microsomal antibodies as discriminant for therapy. , 1987, JAMA.

[28]  E. Krenning,et al.  The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle‐aged women: associations with serum lipids , 1993, Clinical endocrinology.

[29]  B. Weintraub,et al.  Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. , 1992, The American journal of medicine.

[30]  S. Homan,et al.  Determining Transition Probabilities , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  K. Caidahl,et al.  A DOUBLE‐BLIND CROSS‐OVER 12‐MONTH STUDY OF l‐THYROXINE TREATMENT OF WOMEN WITH ‘SUBCLINICAL’ HYPOTHYROIDISM , 1988, Clinical endocrinology.

[32]  A. Alexandrov,et al.  Cost of Acute Stroke Care in Toronto, Canada , 1994, Stroke.

[33]  A. Toft.  Drug therapy : thyroxine therapy , 1994 .

[34]  W. Castelli,et al.  The aging thyroid. Thyroid deficiency in the Framingham Study. , 1985, Archives of internal medicine.

[35]  P. Doubilet,et al.  The cost of underutilization. Percutaneous transluminal angioplasty for peripheral vascular disease. , 1984, The New England journal of medicine.

[36]  L. Wilkins.  National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994 .

[37]  H. Bürgi,et al.  PREVALENCE OF VARIOUS DEGREES OF HYPOTHYROIDISM AMONG PATIENTS OF A GENERAL MEDICAL DEPARTMENT , 1981, Clinical endocrinology.

[38]  W. Harris,et al.  The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. , 1993, The New England journal of medicine.

[39]  W. Patsch,et al.  Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). , 1995, Metabolism: clinical and experimental.

[40]  M. Falkenberg,et al.  Screening of an elderly female population for hypo- and hyperthyroidism by use of a thyroid hormone panel. , 2009, Acta medica Scandinavica.

[41]  J. Lee,et al.  Patient Preferences for Stroke Outcomes , 1994, Stroke.

[42]  J W Hay,et al.  Medical costs of coronary artery disease in the United States. , 1990, The American journal of cardiology.

[43]  F A Sonnenberg,et al.  Commentary: Fine-tuning Life-espectancy Calculations Using Markov Processes , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[44]  T. Parkin,et al.  Treatment of heart disease associated with myxedema. , 1961, Progress in cardiovascular diseases.

[45]  M. Weinstein,et al.  A cost-effectiveness analysis of exercise as a health promotion activity. , 1988, American journal of public health.

[46]  K. Schulman,et al.  Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. , 1990, JAMA.

[47]  A P Cheung,et al.  A cost‐effectiveness analysis of hormone replacement therapy in the menopause∗ , 1992, The Medical journal of Australia.

[48]  S. Grundy,et al.  Individual Responses to a Cholesterol-Lowering Diet in 50 Men With Moderate Hypercholesterolemia , 1994 .

[49]  Paul M. Weber,et al.  Detecting Unsuspected Thyroid Dysfunction by the Free Thyroxine Index , 1980 .

[50]  P. Lundberg,et al.  Thyroid disease and high concentration of serum thyrotrophin in a population sample of women. A 4-year follow-up. , 2009, Acta medica Scandinavica.